Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company has shown impressive growth in overseas business and has made significant breakthroughs in high-end products [5] - Revenue forecasts for 2025-2027 are projected at 126.04 billion, 151.57 billion, and 182.24 billion yuan, with year-on-year growth rates of 22.37%, 20.25%, and 20.24% respectively [6] - The net profit attributable to the parent company for the same period is expected to be 18.71 billion, 22.87 billion, and 27.87 billion yuan, with growth rates of 48.26%, 22.23%, and 21.85% respectively [6] Financial Performance Summary - In 2024, the company achieved a revenue of 103.00 billion yuan (down 9.73% year-on-year) and a net profit of 12.62 billion yuan (down 36.09% year-on-year) [8] - For Q1 2025, the company reported a revenue of 24.78 billion yuan (up 5.42% year-on-year) and a net profit of 3.70 billion yuan (up 1.87% year-on-year) [8] - The company's main business gross margin for 2024 was 49.40%, an increase of 1.85 percentage points year-on-year [8] Market Position and Product Development - The company has seen a steady increase in domestic market share, with a rise of over 3 percentage points, and a nearly 5 percentage point increase in high-end product market share [8] - The company launched over 140 innovative products by the end of 2024, with 49 products receiving FDA registration [8]